Keywords: Novartis, Afinitor, Breast cancer, Ph III

Novartis plans breast cancer filing for Afinitor by year-end

Article | 06 July 2011

Print This

As a result of strong Phase III clinical data with its already marketed kidney cancer drug Afinitor (everolimus), Swiss drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in